Saranas’ transcatheter internal bleeding detector scores FDA de novo clearance

Saranas Early Bird
The device measures changes in electrical resistance across the blood vessel to alert physicians of ruptures or tears during transcatheter procedures. (Saranas)

Saranas has received a de novo clearance from the FDA for its Early Bird system, used to detect internal bleeding in real time during endovascular procedures.

Invented at the Texas Heart Institute, the device includes a sensor-laden vascular access sheath that measures changes in electrical resistance across the blood vessel.

It can alert physicians if the vessel is accidentally torn or injured during transcatheter aortic valve replacements, large-bore hemodynamic support procedures, and other complex interventions where the femoral artery or vein is used.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

“Peri-procedural bleeding associated with endovascular procedures has a significant impact on patient safety and adds incremental costs to the healthcare system with longer hospital stays and additional interventional treatment,” Saranas’ chief medical officer, Philippe Généreux, M.D., said in a statement.

According to the company, a recent study of over 17,000 large-bore interventions found bleeding complications occurred in about 20% of patients.

RELATED: Saranas raises $2.8M to pilot its internal bleeding detector

The Houston-based Saranas is currently piloting the system in multiple centers to assess its versatility, with a commercial launch planned for select centers of excellence in the U.S., the company said.

“As the first and only device on the market for early bleed detection, we have the potential to significantly reduce bleeding complications and related healthcare costs, while improving clinical outcomes in patients undergoing endovascular procedures,” said Saranas President and CEO Zaffer Syed.

Suggested Articles

The Chan Zuckerberg Initiative is awarding $17 million for advances in digital microscopy to allow researchers to view the subtleties of disease.

The drug failed to clearly outperform a generic used as a control, leaving room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq.

The level of interest in gene therapies has been laid bare by a report on Biogen’s pursuit of Nightstar Therapeutics.